Arcutis Biotherapeutics, Inc. (ARQT)
Automate Your Wheel Strategy on ARQT
With Tiblio's Option Bot, you can configure your own wheel strategy including ARQT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ARQT
- Rev/Share 2.0746
- Book/Share 1.0943
- PB 18.0571
- Debt/Equity 0.7927
- CurrentRatio 3.2018
- ROIC -0.3476
- MktCap 2369324341.0
- FreeCF/Share -0.5616
- PFCF -33.2206
- PE -26.905
- Debt/Assets 0.3126
- DivYield 0
- ROE -0.6262
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ARQT | Goldman | -- | Neutral | -- | $18 | July 25, 2025 |
| Initiation | ARQT | H.C. Wainwright | -- | Buy | -- | $19 | Dec. 30, 2024 |
| Initiation | ARQT | Jefferies | -- | Buy | -- | $15 | Aug. 28, 2024 |
News
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
WESTLAKE VILLAGE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- WESTLAKE VILLAGE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter and year ended December 31, 2024, and provided a business update.
Read More
Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZORYVE® (roflumilast) cream 0.05% improved atopic dermatitis (AD) across all primary and secondary efficacy endpoints, with significant improvement as early as Week 1 on multiple efficacy endpoints. 39.4% of children treated with roflumilast cream 0.05% achieved a 75% improvement in Eczema Area and Severity Index (EASI-75), a key secondary endpoint.
Read More
Arcutis to Present at the TD Cowen 45th Annual Health Care Conference
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
WESTLAKE VILLAGE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the TD Cowen 45th Annual Health Care Conference, taking place March 3-5, 2025.
Read More
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 51.64%: Read This Before Placing a Bet
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 51.6% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
About Arcutis Biotherapeutics, Inc. (ARQT)
- IPO Date 2020-01-31
- Website https://www.arcutis.com
- Industry Biotechnology
- CEO Todd Franklin Watanabe
- Employees 342